REFERENCES
- Sogani PC, Fair WR. Treatment of advanced prostatic cancer. Urol Clin North Am 1987; 14: 353–371.
- Schaffer DL, Pendergrass HP. Comparisons of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastasis from carcinoma of the prostate. Radiology 1976; 121: 431–434.
- Smith PH, Bono A, Calais da Silva, Debryune F, Denis L, Robinson P, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. Cancer 1990; 66: 1009–1016.
- Lund F, Smith PH, Suciu S, EORTC Gu Group. Do bone scans predict prognosis in prostatic cancer? A report of the EORTC Protocol 30762. Br J Urol 1984; 56: 58–63.
- Crob JC, Lallot C, Methlin G Bollack. Quantitative bone scintigraphy: Usefulness in the survey of patients treated for bone metastasis of prostatic cancer. Eur Urol 1988; 15: 1993–1995.
- Cooper EH, Robinson MRG, Whelan P, Ferro MA. Tumor markers in prostatic cancer. Cancer 1992; 70: 225–229.
- Coleman RE, Mashietr G, Fogelman I, et al. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol 1988; 24: 1211–1217.
- Arai Y, Takeuchi H, Oishi K, Yoshida O. Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advance prostate cancer? Prostate 1992; 20: 169–177.
- de Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso Smith PH, de Pauw M,EORTC GU GROUP. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from 2 European Organization for Research on Treatment of Cancer trials. J Urol 1989; 141: 883–888.
- Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–1161.
- Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907–923.
- Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57–60.
- Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141: 1070–1075.
- Hopkins SC, Nissenkorn I, Palmieri GMA, Ikard M, Moinuddin M, Soloway MS. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. J Urol 1983; 129: 319–323.
- Risteli L, Risteli J. Non-invasive methods for detection of organ fibrosis. In Rojkind M ed. Focus on connective tissue in health and disease, Boca Raton, FL: CRC, 1990, Vol. 1, pp. 61–98.
- Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988; 34: 715–718.
- Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline crosslinked carboxyterminal type-I Collagen—a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635–640.
- Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328–1332.
- Hassager C, Jensen LT, Johansen JS, Riis BJ, Melkko J, Pôdenphant J, et al. The carboxyterminal propeptide of type I procollagen in serum as a marker of bone formation: The effect of nadrolone decanoate and female sex hormones. Metabolism 1991; 40: 205–208.
- Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993; 29A: 821–825.
- Begg CB. Statistical method in medical diagnosis. CRC Crit. Rev. Med. Information, I: 1, 1986.
- Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992; 147: 931–934.
- Cooper EH, Armitage TG, Robinson MRG, Newling DWW, Richards BR, Smith PH, et al. Prostatis specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990; 66: 1025–1028.